BioCryst Pharmaceuticals (NASDAQ:BCRX) Hits New 12-Month Low at $4.44

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) hit a new 52-week low on Friday . The company traded as low as $4.44 and last traded at $4.47, with a volume of 668065 shares. The stock had previously closed at $4.50.

Analyst Ratings Changes

Separately, Needham & Company LLC restated a “buy” rating and set a $12.00 price objective on shares of BioCryst Pharmaceuticals in a report on Wednesday, April 10th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $13.29.

BioCryst Pharmaceuticals Stock Performance

The company has a 50 day simple moving average of $5.24 and a two-hundred day simple moving average of $5.62.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, February 26th. The biotechnology company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.04). The business had revenue of $93.40 million for the quarter, compared to analyst estimates of $89.19 million. As a group, equities research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.68 earnings per share for the current year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Fifth Third Bancorp raised its position in BioCryst Pharmaceuticals by 17,500.0% during the third quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 3,500 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in BioCryst Pharmaceuticals by 96.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company’s stock worth $34,000 after buying an additional 2,388 shares in the last quarter. Fairfield Bush & CO. acquired a new stake in BioCryst Pharmaceuticals during the first quarter valued at $34,000. State of Wyoming acquired a new stake in BioCryst Pharmaceuticals during the fourth quarter valued at $35,000. Finally, Advisory Services Network LLC increased its holdings in BioCryst Pharmaceuticals by 46.3% in the first quarter. Advisory Services Network LLC now owns 4,740 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 1,500 shares in the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.